Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.4352W HIGH $3.23
Volume
279.50 K
Value Traded
544.74 K
Short % Float
2.49%
Days to Cover
16.1
-3.05%Week
-18.03%1 Month
-19.75%3 Month
-34.59%6 Month
-66.71%5 Year
-72.77%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
179.51 M
EPS (TTM)
0.37
P/E Ratio
5.18
Ent. Value
132.73 M
Total Shares
94.73 M
Float Shares
94.37 M
Insiders
0.37%
Institutions
15.14%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
CGEN Catalyst Timeline
Dated clinical, regulatory and corporate events for Compugen Ltd.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Compugen Ltd.
568Total events
6Upcoming
46Tier-1 (high impact)
2015 to 2036Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPresentation
Compugen management fireside chat at H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference
◆Poster PresentationCOM701Presentation
Trial-in-progress poster on MAIA-ovarian Phase 1 study of COM701 at ESMO Gynaecological Cancers Congress 2026
relapsed platinum sensitive ovarian cancersource ↗
◆Oral PresentationPresentation
Compugen management to participate in Jones Trading Fireside Chat Series
◆Oral PresentationrilvegostomigPresentation
New rilvegostomig data to be released at ASCO 2026
multiple tumor typessource ↗
◆Oral PresentationPresentation
Compugen management presentation at 2026 Stifel Virtual Targeted Oncology Forum
▲Enrollment UpdateCOM701Trial
MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel, and France
relapsed platinum sensitive ovarian cancersource ↗
▲Trial InitiationrilvegostomigTrial
AstraZeneca advancing rilvegostomig across 11 ongoing Phase 3 trials
multiple tumor typessource ↗
▲Trial InitiationGS-0321Trial
Gilead-partnered GS-0321 Phase 1 trial continues to progress as planned
cancersource ↗
◆Oral PresentationPresentation
Management presentation at 25th Annual Needham Virtual Healthcare Conference
▲Oral PresentationrilvegostomigPresentation
Late-breaking Phase 2 data in HER2-positive gastric cancer presented at AACR 2026
HER2-positive gastric cancersource ↗
◆Interim AnalysisCOM701Trial
Interim analysis of sub-trial 1 planned
relapsed platinum sensitive ovarian cancersource ↗
◆Oral PresentationPresentation
Leerink Partners 2026 Global Healthcare Conference fireside chat
◆Oral PresentationPresentation
Oppenheimer 36th Annual Healthcare Life Sciences Conference fireside chat
▲Oral PresentationrilvegostomigPresentation
First overall survival readout presented at ASCO 2026
first-line biliary tract cancersource ↗
▲Partnership / LicenserilvegostomigCorporate
Compugen monetizes portion of rilvegostomig future royalties to AstraZeneca
▲Runway Guidance UpdateCorporate
Cash runway extended into 2029 assuming no further cash inflows
◆Oral PresentationPresentation
Compugen management fireside chat at Stifel 2025 Healthcare Conference
◆Poster PresentationCOM503Presentation
Trial in progress poster presentation of COM503 (GS-0321) at SITC 2025
advanced solid malignanciessource ↗
◆Poster PresentationCOM701Presentation
Pooled analysis of COM701 Phase 1 trials in platinum resistant ovarian cancer at ESMO 2025
platinum resistant ovarian cancersource ↗
◆AbstractCOM701Presentation
Abstract released for pooled analysis of COM701 in PROC at ESMO 2025
platinum resistant ovarian cancersource ↗
◆Oral PresentationrilvegostomigPresentation
Oral presentations of rilvegostomig (PD-1/TIGIT bispecific) at ESMO 2025 by AstraZeneca
solid tumorssource ↗
◆Poster PresentationCOM701Presentation
Pooled analysis from three Phase 1 trials of COM701 to be presented at ESMO 2025
platinum resistant ovarian cancersource ↗
◆Poster PresentationrilvegostomigPresentation
Updated rilvegostomig data from ARTEMIDE-01 in NSCLC at ESMO 2025
metastatic NSCLCsource ↗
◆Poster PresentationPresentation
Bin2Niche: A spatial transcriptomics framework reveals immune-defined epithelial niches in MSI colorectal cancer
MSI colorectal cancersource ↗
◆Oral PresentationPresentation
Fireside chat at H.C. Wainwright 27th Annual Global Investment Conference
◆Management ChangeCorporate
Anat Cohen-Dayag appointed Executive Chair, Eran Ophir appointed President and CEO, Paul Sekhri steps down as Chair
▲Oral PresentationCOM701Presentation
Pooled Phase 1 data presented at ESMO 2025
platinum resistant ovarian cancersource ↗
▲Oral PresentationrilvegostomigPresentation
AstraZeneca presented ARTEMIDE-01 data at ESMO
checkpoint naïve NSCLCsource ↗
▲First Patient DosedCOM701Trial
First patient dosed in sub-trial 1 of MAIA-ovarian platform trial
relapsed platinum sensitive ovarian cancersource ↗
◆Poster PresentationPresentation
Poster presentation at ISCB/ECCB 2025: Computational prediction of TNBC tumor subtypes from an integrative single cell atlas elucidates immune evasion and immunotherapy resistance mechanisms
TNBCsource ↗
▲First Patient DosedCOM701Trial
First patient dosed in MAIA-ovarian platform trial of COM701 maintenance therapy
platinum sensitive ovarian cancersource ↗
◆Poster PresentationPresentation
Poster presentation at EACR 2025: Prediction of immune evasion and immunotherapy resistance mechanisms associated with distinct TNBC subtypes
TNBCsource ↗
◆Oral PresentationrilvegostomigPresentation
AstraZeneca to present primary analysis of rilvegostomig + chemo at ASCO 2025
first-line advanced biliary tract cancersource ↗
◆Oral PresentationPresentation
H.C. Wainwright 2nd Annual AI Based Drug Discovery & Development Conference
◆Trial InitiationCOM701Trial
Initiate adaptive platform trial sub-study 1 of COM701 in PSOC maintenance
relapsed platinum sensitive ovarian cancersource ↗
◆Oral PresentationPresentation
Fireside chat at Leerink Partners Global Healthcare Conference
◆Quarterly UpdateCorporate
Q4 and full year 2024 financial results release and conference call
●Poster PresentationPresentation
Poster presentation at AGBT 2025: Using 3' Single Cell Sequencing to Study Patient-Derived Tumor Cells Reveals Enhanced Potential to Study Differential Splicing at the Cell Type Level
Past FDA Catalysts and PDUFA Decisions
How CGEN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-10-18 | COM701 (anti-PVRIG antibody) | phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 69%
Micro Cap(rank 454 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| COM701 Small moleculeNCT06888921 | Ovarian Cancer | Phase 1 | ACTIVE NOT_RECRUITING | 60 | Mar 1, 2027 | ||||||
| COM503 Small moleculeNCT06759649 | Neoplasm | Phase 1 | RECRUITING | 200 | Nov 22, 2027 | ||||||
| COM701 Small moleculeCompletedNCT03667716 | Advanced Cancer | Phase 1 | COMPLETED | 121 | Jan 30, 2024 | ||||||
| Dose escalation: COM902 monotherapy Small moleculeCompletedNCT04354246 | Advanced Cancer | Phase 1 | COMPLETED | 94 | Apr 1, 2026 | ||||||
| COM701 Small moleculeCompletedNCT04570839 | Endometrial Neoplasms | Phase 1 | COMPLETED | 48 | May 15, 2024 |
Clinical Trial Results
Readouts, endpoints and source filings for every CGEN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| COM701 | platinum-resistant ovarian cancer | Phase 1 | 2025-10-13 | The pooled analysis of 60 evaluable patients with platinum-resistant ovarian cancer demonstrated that COM701 was well tolerated and showed consistent, durable responses, particularly in patients without liver metastases, supporting its potential as a maintenance therapy.Read More | Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Levine ZuritOfficer (SVP, Business Development) | Option | 1,875 31,250 held | $0.83 | 07/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CGEN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.7 % | 6.81 M | 3.18 M | -3.97% ( -131.59 K) |
CGEN Institutional Ownership Trends
CGEN Short Interest
Shares sold short, counted twice a month.
2.49%
Short % of Float
of tradable shares sold short
2.4M
Shares Sold Short
-0.5% vs prior count
16.1 Very high
Days to Cover
trading days of normal volume to buy every short share back
146.2K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CGEN ranks across every disease it competes in
Competitive Position is a premium feature
See how CGEN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCGEN News
CGEN▼ -2.3%today
Compugen to Release Third Quarter 2026 Results on Monday, November 9, 2026
Compugen Ltd. will release its third quarter 2026 financial results on November 9, 2026, before U.S. markets open. A conference call will follow at 8:30 AM ET to discuss the results and provide updates. The company focuses on cancer immunotherapy and utilizes AI for drug target discovery.
Read more →CGENCompugen to Participate in a Fireside Chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference
Compugen Ltd. will participate in a fireside chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference on October 8, 2026. The event will be held virtually, and a live webcast will be available on Compugen's website. The company is known for its AI-driven cancer immunotherapy pipeline, including several promising candidates in clinical trials.
Read more →CGENCompugen to Host Virtual KOL Event on COM701 in Ovarian Cancer & Unigen™ Platform Update on October 5, 2026
Compugen Ltd. will host a virtual KOL event on October 5, 2026, featuring Dr. Oladapo Yeku to discuss COM701, a potential first-in-class anti-PVRIG antibody for ovarian cancer. The event will cover the MAIA-ovarian trial's adaptive design and the company's Unigen™ platform advancements. Interim data on progression-free survival is expected by Q1 2027.
Read more →CGENCompugen to Participate in a Fireside Chat at the H.C. Wainwright 28th Annual Global Investment Conference
Compugen Ltd. will participate in a fireside chat and hold one-on-one meetings at the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026, in New York City. The event will feature a live webcast of the presentation, available on Compugen's website. The company is known for its AI-driven cancer immunotherapy development.
Read more →CGENCompugen Reports Second Quarter 2026 Results
Compugen Ltd. reported its second quarter 2026 results, highlighting progress in the MAIA-ovarian trial for COM701, with median progression-free survival data expected by Q1 2027. The company maintains a solid financial position with cash reserves projected to last until 2029. Additionally, partnered programs with AstraZeneca and Gilead continue to advance, showcasing promising developments in cancer treatment.
Read more →CGEN▲ +6.4%on this news
Compugen to Participate in BTIG Biotechnology Conference 2026
Compugen Ltd. will participate in the BTIG Biotechnology Conference 2026, scheduled for July 28-29, 2026. The company will present and hold one-on-one meetings with attendees. Compugen is known for its AI/ML-powered platform for cancer immunotherapy and has several clinical trials underway for its drug candidates.
Read more →CGENCompugen to Release Second Quarter 2026 Results on Monday, August 3, 2026
Compugen Ltd. announced it will release its second quarter 2026 financial results on August 3, 2026, before U.S. markets open. A conference call and webcast will follow at 8:30 AM ET to discuss the results and provide a corporate update. The company is known for its AI/ML-driven cancer immunotherapy development.
Read more →CGENCompugen Presents a Trial-in-Progress Poster on the MAIA-ovarian Adaptive Platform Trial at ESMO Gynaecological Cancers Congress
Compugen Ltd. presented a trial-in-progress poster for the MAIA-ovarian adaptive platform trial of COM701 at the ESMO Gynaecological Cancers Congress 2026. This trial evaluates COM701, a potential first-in-class anti-PVRIG antibody, as a maintenance treatment for relapsed platinum-sensitive ovarian cancer. Initial data from the trial is anticipated by Q1 2027.
Read more →CGENCompugen to Present Phase 1 MAIA-Ovarian Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026
Compugen Ltd. announced it will present a trial-in-progress poster on its MAIA-ovarian Phase 1 study of COM701 at the ESMO Gynaecological Cancers Congress 2026. The study evaluates the safety and efficacy of COM701 in treating relapsed platinum-sensitive ovarian cancer. The presentation is scheduled for June 18, 2026, in Copenhagen.
Read more →CGENCompugen to Participate in Jones Trading Fireside Chat Series with Leaders in AI/ML-based Drug Development
Compugen Ltd. announced its participation in Jones Trading's Fireside Chat Series focused on AI/ML-based drug development. The event is scheduled for June 15, 2026, and will feature insights from Compugen's management. The company is known for its AI/ML powered platform for cancer immunotherapy discovery and has several clinical-stage programs underway.
Read more →CGENCompugen Reports First Quarter 2026 Results
Compugen Ltd. reported its first quarter 2026 financial results, highlighting the ongoing enrollment in the COM701 MAIA-ovarian trial across clinical sites in the U.S., Israel, and France, with an interim analysis expected by Q1 2027. The company also noted the advancement of its partner AstraZeneca's rilvegostomig through 11 Phase 3 trials, with new data to be presented. Compugen maintains a solid financial position with a cash runway projected into 2029, leveraging partnerships that could yield substantial milestone payments. Despite these optimistic developments, the company reported an increased net loss compared to the previous year, raising potential financial concerns.
Read more →CGENCompugen to Participate in 2026 Stifel Virtual Targeted Oncology Forum
Compugen Ltd. will present at the 2026 Stifel Virtual Targeted Oncology Forum on May 19, 2026. The event will feature a live webcast accessible via the company's Investor Relations page. Compugen is recognized for its AI/ML-powered therapeutic discovery platform, focusing on novel cancer immunotherapies.
Read more →CGENCompugen to Release First Quarter 2026 Results on Monday, May 18, 2026
Compugen Ltd. announced it will release its first quarter 2026 financial results on May 18, 2026, before U.S. markets open. A conference call and webcast will follow at 8:30 AM ET to discuss the results and provide corporate updates. The company continues to develop innovative cancer immunotherapy programs.
Read more →CGEN▲ +8.3%on this news· ran to +26% by day 3
Compugen to Participate in 25th Annual Needham Virtual Healthcare Conference
Compugen Ltd. announced its participation in the 25th Annual Needham Virtual Healthcare Conference, scheduled for April 13, 2026. The company's management will present from 8:45 to 9:25 AM ET, with a live webcast available on their website. Compugen is known for its AI-driven drug target discovery and has several promising cancer immunotherapy programs.
Read more →CGEN▲ +24.3%on this news
Compugen Reports Fourth Quarter and Full Year 2025 Results
Compugen Ltd. reported strong financial results for Q4 and full year 2025, highlighting a strategic monetization deal with AstraZeneca that extends its cash runway into 2029. The company initiated new clinical trials and presented supportive data for its MAIA-ovarian trial at ESMO 2025. Despite significant revenue growth, Compugen acknowledges risks related to clinical development and reliance on partnerships.
Read more →CGEN▲ +5.3%on this news
Compugen to Participate in Upcoming Investor Conferences
Compugen Ltd. (NASDAQ: CGEN) announced its participation in two upcoming investor conferences, the Oppenheimer 36th Annual Healthcare Life Sciences Conference and the Leerink Partners 2026 Global Healthcare Conference. The company will engage in fireside chats and 1x1 meetings at both events. Compugen is known for its AI/ML-powered computational drug discovery platform and has several promising cancer immunotherapy programs in development. The participation in these conferences highlights the company’s efforts to connect with investors and discuss its innovative pipeline.
Read more →CGENCompugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
Compugen Ltd. announced the release date for its fourth quarter and full year 2025 financial results, scheduled for March 2, 2026, before market opening. The company will also host a conference call and webcast at 8:30 AM ET to review the results. As a clinical-stage cancer immunotherapy firm leveraging AI/ML, Compugen aims to advance its therapeutic discoveries, including its innovative drug candidates targeting TIGIT and PVRIG.
Read more →CGENCompugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
Compugen Ltd. has appointed Michele Holcomb, Ph.D., as an independent director, effective February 11, 2026. Dr. Holcomb brings over 30 years of experience in the biotech and pharmaceutical sectors, which is expected to strengthen the board's capabilities. Compugen is well-positioned financially and has multiple promising clinical programs underway.
Read more →CGENCompugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
Compugen agreed to sell a portion of future royalties for rilvegostomig to AstraZeneca. The deal provides an upfront payment of $65 million and up to $25 million upon regulatory acceptance. This transaction extends the company's cash runway into 2029. Compugen retains the majority of its royalty interest in the drug.
Read more →About Compugen Ltd.
BIOPHARMAWATCH ELITE PLUS
Trade the next CGEN catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime